Aeterna Zentaris Stock Forecast, Price & News

Wall Street analysts have given Aeterna Zentaris a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aeterna Zentaris wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Aeterna Zentaris is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Aeterna Zentaris.

Aeterna Zentaris Inc. (NASDAQ:AEZS) posted its quarterly earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter. The biopharmaceutical company had revenue of $0.60 million for the quarter. Aeterna Zentaris had a negative net margin of 161.21% and a negative trailing twelve-month return on equity of 15.42%.
View Aeterna Zentaris' earnings history.

Aeterna Zentaris' stock was trading at $0.6795 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AEZS stock has decreased by 8.1% and is now trading at $0.6244.
View which stocks have been most impacted by COVID-19.

Some companies that are related to Aeterna Zentaris include DURECT (DRRX), Taiwan Liposome (TLC), TherapeuticsMD (TXMD), XOMA (XOMA), Nature's Sunshine Products (NATR), Wave Life Sciences (WVE), Millendo Therapeutics (MLND), CTI BioPharma (CTIC), Impel NeuroPharma (IMPL), Puma Biotechnology (PBYI), Inozyme Pharma (INZY), Theratechnologies (THERF), Terns Pharmaceuticals (TERN), Vincerx Pharma (VINC) and Sernova (SEOVF).
View all of AEZS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aeterna Zentaris investors own include Zosano Pharma (ZSAN), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), Cannabics Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Novan (NOVN) and Washington Prime Group (WPG).

Aeterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

Aeterna Zentaris' stock is owned by a variety of retail and institutional investors. Top institutional investors include Susquehanna International Group LLP (0.00%), Natixis (0.18%), Virtu Financial LLC (0.15%), Goldman Sachs Group Inc. (0.14%), Renaissance Technologies LLC (0.09%) and Group One Trading L.P. (0.00%).

AEZS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, HAP Trading LLC, and Sabby Management LLC.

AEZS stock was acquired by a variety of institutional investors in the last quarter, including Natixis, Goldman Sachs Group Inc., Susquehanna International Group LLP, Renaissance Technologies LLC, Group One Trading L.P., Simplex Trading LLC, Virtu Financial LLC, and Citadel Advisors LLC.

Shares of AEZS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AEZS stock can currently be purchased for approximately $0.62.

Aeterna Zentaris has a market capitalization of $75.74 million and generates $3.65 million in revenue each year.

Aeterna Zentaris employs 11 workers across the globe.

The official website for Aeterna Zentaris is www.zentaris.com.

Aeterna Zentaris is headquartered at 315 Sigma Drive South Carolina, Summerville SC, 29486.

Aeterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The biopharmaceutical company can be reached via phone at (843) 900-3223 or via email at [email protected].